首页> JCO precision oncology> Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

导出 LinkOut

翻译打印收藏纠错

第一作者： Philippe L,Bedard

第一单位： Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

作者： Philippe L,Bedard ^[1] ; Shuli,Li ^[2] ; Kari B,Wisinski ^[3] ; Eddy S,Yang ^[4] ; Sewanti A,Limaye ^[5] ; Edith P,Mitchell ^[6] ; James A,Zwiebel ^[7] ; Jeffrey A,Moscow ^[8] ; Robert J,Gray ^[9] ; Victoria,Wang ^[9] ; Lisa M,McShane ^[10] ; Larry V,Rubinstein ^[10] ; David R,Patton ^[11] ; P Mickey,Williams ^[12] ; Stanley R,Hamilton ^[13] ; Barbara A,Conley ^[14] ; Carlos L,Arteaga ^[15] ; Lyndsay N,Harris ^[14] ; Peter J,O'Dwyer ^[16] ; Alice P,Chen ^[17] ; Keith T,Flaherty ^[18]

作者单位： Princess Margaret Cancer Centre, Toronto, Ontario, Canada. ^[1] E-A Biostatistical Center, Boston, MA. ^[2] University of Wisconsin Carbone Cancer Center, Madison, WI. ^[3] University of Alabama-Birmingham, Birmingham, AL. ^[4] Kokilaben Dhirubhai Ambani Hospital, Mumbai, India (Current). ^[5] Thomas Jefferson University Hospital, Philadelphia, PA. ^[6] Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. ^[7] Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. ^[8] Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA. ^[9] Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. ^[10] Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD. ^[11] Frederick National Laboratory for Cancer Research, Frederick, MD. ^[12] City of Hope National Medical Center, Duarte, CA. ^[13] Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. ^[14] UT Southwestern Simmons Cancer Cancer Center, Dallas, TX. ^[15] University of Pennsylvania, Philadelphia, PA. ^[16] Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. ^[17] Massachusetts General Hospital, Boston, MA. ^[18]

主题词乳腺肿瘤(Breast Neoplasms);腹泻(Diarrhea);女(雌)性(Female);人类(Humans);原位杂交, 荧光(In Situ Hybridization, Fluorescence);男(雄)性(Male);中年人(Middle Aged);突变(Mutation);国立癌症研究所(美国)(National Cancer Institute (U.S.));喹唑啉类(Quinazolines);受体, 雌激素(Receptors, Estrogen);每搏输出量(Stroke Volume);美国(United States);心室功能, 左(Ventricular Function, Left)

DOI 10.1200/PO.22.00165

PMID 35939768

发布时间 2024-09-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

JCO precision oncology

2022年6卷

e2200165页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

JCO precision oncology

2022年6卷

e2200165页

检索历史清除

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

JCO precision oncology

相似文献

JCO precision oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

JCO precision oncology

相似文献

JCO precision oncology

相关期刊

检索历史清除